Cargando…

Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with RAS Wild-Type Left-Sided Tumours in Canada

Minimal Canadian data are available on the RAS testing rates, treatment patterns, and corresponding overall survival (OS) in metastatic colorectal cancer (mCRC) patients. We conducted a population-based cohort study of left-sided RAS wild-type (WT) mCRC patients diagnosed between 1 January 2014 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyne, Devon J., Ngan, Elaine, Carbonell, Chantelle, Wani, Rajvi J., Cirone Morris, Carlye, Martinez, Daniel Jun, Cheung, Winson Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528146/ https://www.ncbi.nlm.nih.gov/pubmed/37754511 http://dx.doi.org/10.3390/curroncol30090596

Ejemplares similares

Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada
por: O’Sullivan, Dylan E., et al.
Publicado: (2023)

Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada
por: Vanderpuye-Orgle, Jackie, et al.
Publicado: (2022)

Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada
por: Alimohamed, Nimira, et al.
Publicado: (2022)

Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis
por: Sati, Neha, et al.
Publicado: (2021)

Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study
por: Martins, Diana, et al.
Publicado: (2023)

Real-World Treatment Patterns, Clinical Outcomes, and Health Care Resource Utilization in Extensive-Stage Small Cell Lung Cancer in Canada
por: O’Sullivan, Dylan E., et al.
Publicado: (2021)

Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens
por: Arikan, Rukiye, et al.
Publicado: (2023)

Selection Bias in Real-World Data Studies Used to Support Health Technology Assessments: A Case Study in Metastatic Cancer
por: Jarada, Tamer N., et al.
Publicado: (2023)

Real-world impact of patient-reported outcome measurement on overall survival, healthcare use and treatment discontinuation in cancer patients
por: Yan, Jessie T, et al.
Publicado: (2023)

Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2022)

First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
por: Liu, Shousheng, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer
por: Han, Jiaqi, et al.
Publicado: (2020)

Understanding real‐world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population‐based cohort study
por: Jimenez‐Zepeda, Victor H., et al.
Publicado: (2022)

Cost-Effectiveness of Anti-Epidermal Growth Factor Receptor Therapy Versus Bevacizumab in KRAS Wild-Type (WT), Pan-RAS WT, and Pan-RAS WT Left-Sided Metastatic Colorectal Cancer
por: Lee, Shing Fung, et al.
Publicado: (2021)

Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer
por: Boyne, Devon J., et al.
Publicado: (2021)

The Role of Wild-Type RAS in Oncogenic RAS Transformation
por: Sheffels, Erin, et al.
Publicado: (2021)

The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy
por: Cai, Changjing, et al.
Publicado: (2022)

Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study
por: Granieri, Stefano, et al.
Publicado: (2022)

Impact of the COVID-19 pandemic on cancer diagnoses, stage and survival in Alberta
por: Heer, Emily, et al.
Publicado: (2023)

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors’ perspective
por: Wills, Allison, et al.
Publicado: (2023)

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis
por: Boyne, Devon J., et al.
Publicado: (2019)

Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta‐analysis
por: Boyne, Devon J., et al.
Publicado: (2020)

Developing a Prediction Model for Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Model Building Approaches
por: Basmadjian, Robert B., et al.
Publicado: (2022)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

Sos-mediated cross activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis
por: Jeng, Hao-Hsuan, et al.
Publicado: (2012)

A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS)
por: Karim, Safiya, et al.
Publicado: (2023)

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
por: Parisi, Alessandro, et al.
Publicado: (2021)

Real-World Use of Granulocyte-Colony Stimulating Factor in Patients with Breast Cancer from Alberta, Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Determinants of COVID-19 Case Fatality Rate in the United States: Spatial Analysis Over One Year of the Pandemic
por: Kathe, Niranjan J., et al.
Publicado: (2021)

Trends in Major Adverse Cardiac Events and Healthcare Resource Utilization During the COVID-19 Pandemic in Alberta, Canada
por: Mackinnon, Erin S., et al.
Publicado: (2023)

Building infrastructure for outcomes-based agreements in Canada: can administrative health data be used to support an outcomes-based agreement in oncology?
por: Cheung, Winson Y., et al.
Publicado: (2022)

Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation
por: Ferguson, Robert, et al.
Publicado: (2023)

The wild side of plant microbiomes
por: Pérez-Jaramillo, Juan E., et al.
Publicado: (2018)

Humanistic burden of disease for patients with advanced melanoma in Canada
por: Cheung, Winson Y., et al.
Publicado: (2018)

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
por: Köhne, Claus-Henning, et al.
Publicado: (2019)

The Sweet Side of HIPK2
por: Garufi, Alessia, et al.
Publicado: (2023)

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis
por: Chen, Datian, et al.
Publicado: (2018)

Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non–Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment
por: Ramagopalan, Sreeram V., et al.
Publicado: (2022)

Controversies in the treatment of RAS wild-type metastatic colorectal cancer
por: Vera, R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lvfk0h004itumbgm71hp26svvj